KRAS mutations, occurring early in pancreatic cancer progression, activate multiple signaling pathways, including Raf/mitogen-activated protein kinase and Akt/protein kinase B, influencing COX-2 transcription. Here, KRAS is linked to pancreatic neoplasm.